Want to see ZURA full AI Analyst Report?
ZURA Stock Chart & Stats
$5.99
$0.15(2.87%)
At close: 4:00 PM EDT
$5.99
$0.15(2.87%)
Day’s Range― - ―
52-Week Range$1.88 - $7.44
Previous Close$5.38
Volume380.37K
Average Volume (3M)1.31M
Market Cap
$605.64M
Enterprise Value$543.01
Total Cash (Recent Filing)$205.13M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 18, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding95,829,140
10 Day Avg. Volume692,013
30 Day Avg. Volume1,310,694
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$21.00Price Target Upside250.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.77
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero debt reduces interest costs and solvency risk, giving Zura greater flexibility to fund clinical development. Higher equity and assets indicate improved capitalization, although this strength depends on managing ongoing losses.
Expanded Clinical PipelineCompleting adequately sized Phase 2 studies while adding polymyalgia rheumatica broadens the lead asset’s opportunity set. Multiple indications can diversify clinical value and improve the potential commercial platform if efficacy is confirmed.
Funding RunwayA multi-year cash runway supports continued development of the three-asset pipeline through important late-2026 and 2027 readouts. It reduces immediate financing pressure and allows management to pursue trials without relying on near-term capital markets.
Bears Say
No Commercial RevenueWithout product revenue, Zura depends on external financing to fund operations and cannot internally support development costs. Commercialization remains contingent on successful trials, regulatory approval, launch execution, and eventual market adoption.
Accelerating Losses And Cash BurnRising losses and deeply negative operating cash flow show that clinical expansion is consuming substantial resources before revenue generation begins. Persistent burn can reduce financial flexibility and create future funding or dilution needs.
Clinical Outcome RiskZura’s value is concentrated in investigational therapies that have not yet demonstrated pivotal efficacy or secured approval. Disappointing safety or efficacy results could impair the pipeline, delay commercialization, and weaken access to future financing.
Zura Bio News
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $1.88 and its highest was $7.44 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $605.64M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is Nov 18, 2026 which is in 83 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Aug 11, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.191 by -$0.019.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.21.
How many shares outstanding does Zura Bio have?
Zura Bio has 95,829,140 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.191. Following the earnings report the stock price went down -1.243%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in ZURA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zura Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (250.58% Upside)
$21.00 (250.58% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 28.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
228.04%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.23%
Trailing 12-Months
Company Description
Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
ZURA Stock 12 Month Forecast
Average Price Target
$21.00
▲(250.58% Upside)
Technical Analysis
Ownership Overview
8.17% Insiders
1.57% Mutual Funds
57.25% Other Institutional Investors
29.09% Public Companies and
Individual Investors